Drug intelligence / Profile preview

ICM20

Development stage: Phase 1
Lead developer: IC-MedTech
Modality: Small Molecules
Administration: Oral

Overview

ICM20 is a small molecule drug developed by Ic Medtech Corp. It is currently in Phase 1 clinical trials for the treatment of Chagas disease. The available data indicate that it is being evaluated as an oral therapy, both alone and in combination with benznidazole, to assess its safety and tolerability in adults diagnosed with Chagas disease. Detailed information about its mechanism of action, molecular target(s), or broader therapeutic applications has not been disclosed in public sources as of June 2025[1][5][9].

Other names: ICM-20 + Std Care

Beyond the preview

Go deeper on ICM20.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ICM20.

Explore the full profile